LT3083562T - Fenoksietilo cikliniai amino dariniai ir jų aktyvumas kaip ep4 receptoriaus moduliatorių - Google Patents
Fenoksietilo cikliniai amino dariniai ir jų aktyvumas kaip ep4 receptoriaus moduliatoriųInfo
- Publication number
- LT3083562T LT3083562T LTEP14827907.8T LT14827907T LT3083562T LT 3083562 T LT3083562 T LT 3083562T LT 14827907 T LT14827907 T LT 14827907T LT 3083562 T LT3083562 T LT 3083562T
- Authority
- LT
- Lithuania
- Prior art keywords
- phenoxyethyl
- activity
- receptor modulators
- cyclic amine
- amine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361916827P | 2013-12-17 | 2013-12-17 | |
| PCT/US2014/069743 WO2015094902A1 (en) | 2013-12-17 | 2014-12-11 | Phenoxyethyl cyclic amine derivatives and their activity as ep4 receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3083562T true LT3083562T (lt) | 2018-01-10 |
Family
ID=52355185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP14827907.8T LT3083562T (lt) | 2013-12-17 | 2014-12-11 | Fenoksietilo cikliniai amino dariniai ir jų aktyvumas kaip ep4 receptoriaus moduliatorių |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9776964B2 (lt) |
| EP (1) | EP3083562B1 (lt) |
| JP (1) | JP6212644B2 (lt) |
| KR (1) | KR101807981B1 (lt) |
| CN (1) | CN105793242B (lt) |
| AU (1) | AU2014366361B2 (lt) |
| BR (1) | BR112016011016A8 (lt) |
| CA (1) | CA2928593A1 (lt) |
| CY (1) | CY1119583T1 (lt) |
| DK (1) | DK3083562T3 (lt) |
| EA (1) | EA028921B1 (lt) |
| ES (1) | ES2651858T3 (lt) |
| HR (1) | HRP20171850T1 (lt) |
| HU (1) | HUE035698T2 (lt) |
| LT (1) | LT3083562T (lt) |
| ME (1) | ME02896B (lt) |
| MX (1) | MX2016007566A (lt) |
| NO (1) | NO3221486T3 (lt) |
| PL (1) | PL3083562T3 (lt) |
| PT (1) | PT3083562T (lt) |
| RS (1) | RS56615B1 (lt) |
| SI (1) | SI3083562T1 (lt) |
| WO (1) | WO2015094902A1 (lt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| HUE056080T2 (hu) | 2017-05-18 | 2022-01-28 | Idorsia Pharmaceuticals Ltd | Fenilszármazékok mint PGE2 receptor modulátorok |
| TW201900178A (zh) | 2017-05-18 | 2019-01-01 | 瑞士商愛杜西亞製藥有限公司 | 作為pge2受體調節劑之嘧啶衍生物 |
| SI3625224T1 (sl) | 2017-05-18 | 2021-11-30 | Idorsia Pharmaceuticals Ltd | N-substituirani indolni derivati |
| CN110621671A (zh) | 2017-05-18 | 2019-12-27 | 爱杜西亚药品有限公司 | 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物 |
| ES2896476T3 (es) | 2017-05-18 | 2022-02-24 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina |
| CN109970625B (zh) * | 2017-12-28 | 2021-02-26 | 新发药业有限公司 | 一种5r-苄氧氨基哌啶-2s-甲酸或其衍生物的制备方法 |
| US20220324803A1 (en) * | 2019-06-11 | 2022-10-13 | Teon Therapeutics, Inc. | Prostaglandin e2 receptor 4 antagonists and uses thereof |
| EP3885339A1 (en) * | 2020-03-27 | 2021-09-29 | Rottapharm Biotech S.r.l. | Process for the preparation of (r)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or a salt thereof |
| TW202228674A (zh) | 2020-11-13 | 2022-08-01 | 日商小野藥品工業股份有限公司 | 藉由併用ｅｐ４拮抗藥與免疫檢查點抑制物質而進行之癌症治療 |
| CN112608271A (zh) * | 2020-11-26 | 2021-04-06 | 安润医药科技（苏州）有限公司 | 酰胺衍生物及其在制备ep4受体拮抗剂中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2500157C2 (de) | 1975-01-03 | 1983-09-15 | Hoechst Ag, 6230 Frankfurt | N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung |
| EP1487437B1 (en) | 2002-03-18 | 2006-08-16 | Pfizer Products Inc. | Use of selective ep4 receptor agonists for the treatment of diseases |
| DE602004015620D1 (de) * | 2003-07-28 | 2008-09-18 | Janssen Pharmaceutica Nv | Benzimidazol-, benzothiazol- und benzoxazolderivate und deren verwendung als lta4h-modulatoren |
| BRPI0414130B8 (pt) | 2003-09-03 | 2021-05-25 | Askat Inc | compostos de fenilamida ou piridilamida, seu uso e composições farmacêuticas que os compreendem. |
| BRPI0510598A (pt) | 2004-05-04 | 2007-11-20 | Pfizer | compostos de amida de aril ou heteroaril substituìdos |
| WO2005105732A1 (en) | 2004-05-04 | 2005-11-10 | Pfizer Japan Inc. | Substituted methyl aryl or heteroaryl amide compounds |
| JP5244091B2 (ja) * | 2006-04-24 | 2013-07-24 | メルク カナダ インコーポレイテッド | Ｅｐ４受容体アンタゴニストとしてのインドールアミド誘導体 |
| CA2654811A1 (en) | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Indoline amide derivatives as ep4 receptor ligands |
| WO2009005076A1 (ja) * | 2007-07-03 | 2009-01-08 | Astellas Pharma Inc. | アミド化合物 |
| EP2565191B1 (en) | 2008-05-14 | 2014-10-08 | Astellas Pharma Inc. | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy |
| JP5536773B2 (ja) | 2008-08-14 | 2014-07-02 | ベータ・ファーマ・カナダ・インコーポレイテッド | Ｅｐ４受容体アンタゴニストとしてのヘテロ環式アミド誘導体 |
| CN102770159A (zh) | 2010-02-22 | 2012-11-07 | 拉夸里亚创药株式会社 | Ep-4受体拮抗剂在治疗il-23介导疾病中的用途 |
| US9120824B2 (en) | 2011-07-04 | 2015-09-01 | Rottapharm Biotech S.R.L. | Cyclic amine derivatives as EP4 receptor agonists |
| CN103702980B (zh) * | 2011-07-04 | 2016-10-05 | 罗达制药生物技术有限责任公司 | 环胺衍生物作为ep4受体拮抗剂 |
| JO3296B1 (ar) * | 2012-06-29 | 2018-09-16 | Lilly Co Eli | مركبات فينوكسي إيثيل بيبريدين |
| TW201443004A (zh) | 2013-02-15 | 2014-11-16 | Lilly Co Eli | 苯氧基乙氧基化合物 |
| TWI636046B (zh) * | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫－１ｈ－異喹啉化合物 |
-
2014
- 2014-12-11 HU HUE14827907A patent/HUE035698T2/en unknown
- 2014-12-11 EA EA201690894A patent/EA028921B1/ru not_active IP Right Cessation
- 2014-12-11 SI SI201430434T patent/SI3083562T1/sl unknown
- 2014-12-11 RS RS20171227A patent/RS56615B1/sr unknown
- 2014-12-11 WO PCT/US2014/069743 patent/WO2015094902A1/en active Application Filing
- 2014-12-11 LT LTEP14827907.8T patent/LT3083562T/lt unknown
- 2014-12-11 MX MX2016007566A patent/MX2016007566A/es unknown
- 2014-12-11 EP EP14827907.8A patent/EP3083562B1/en active Active
- 2014-12-11 CN CN201480068170.1A patent/CN105793242B/zh not_active Expired - Fee Related
- 2014-12-11 JP JP2016538744A patent/JP6212644B2/ja not_active Expired - Fee Related
- 2014-12-11 ME MEP-2017-238A patent/ME02896B/me unknown
- 2014-12-11 DK DK14827907.8T patent/DK3083562T3/da active
- 2014-12-11 ES ES14827907.8T patent/ES2651858T3/es active Active
- 2014-12-11 PT PT148279078T patent/PT3083562T/pt unknown
- 2014-12-11 US US15/030,888 patent/US9776964B2/en not_active Expired - Fee Related
- 2014-12-11 AU AU2014366361A patent/AU2014366361B2/en not_active Ceased
- 2014-12-11 BR BR112016011016A patent/BR112016011016A8/pt not_active IP Right Cessation
- 2014-12-11 PL PL14827907T patent/PL3083562T3/pl unknown
- 2014-12-11 KR KR1020167015741A patent/KR101807981B1/ko active IP Right Grant
- 2014-12-11 CA CA2928593A patent/CA2928593A1/en not_active Abandoned
-
2015
- 2015-10-02 NO NO15775410A patent/NO3221486T3/no unknown
-
2017
- 2017-11-09 CY CY20171101176T patent/CY1119583T1/el unknown
- 2017-11-28 HR HRP20171850TT patent/HRP20171850T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR101807981B1 (ko) | 2017-12-11 |
| CA2928593A1 (en) | 2015-06-25 |
| US20160272585A1 (en) | 2016-09-22 |
| SI3083562T1 (sl) | 2017-11-30 |
| JP2016540007A (ja) | 2016-12-22 |
| ES2651858T3 (es) | 2018-01-30 |
| AU2014366361B2 (en) | 2017-04-20 |
| EP3083562A1 (en) | 2016-10-26 |
| NO3221486T3 (lt) | 2018-09-08 |
| BR112016011016A8 (pt) | 2018-01-30 |
| EP3083562B1 (en) | 2017-09-27 |
| EA028921B1 (ru) | 2018-01-31 |
| CY1119583T1 (el) | 2018-03-07 |
| DK3083562T3 (da) | 2017-11-13 |
| ME02896B (me) | 2018-04-20 |
| CN105793242A (zh) | 2016-07-20 |
| HUE035698T2 (en) | 2018-05-28 |
| RS56615B1 (sr) | 2018-02-28 |
| EA201690894A1 (ru) | 2016-10-31 |
| KR20160084467A (ko) | 2016-07-13 |
| AU2014366361A1 (en) | 2016-05-19 |
| PL3083562T3 (pl) | 2018-02-28 |
| PT3083562T (pt) | 2017-12-13 |
| WO2015094902A1 (en) | 2015-06-25 |
| MX2016007566A (es) | 2016-10-03 |
| US9776964B2 (en) | 2017-10-03 |
| HRP20171850T1 (hr) | 2018-01-12 |
| JP6212644B2 (ja) | 2017-10-11 |
| CN105793242B (zh) | 2018-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171850T1 (hr) | Fenoksietilni derivati prstenastog amina i njihova aktivnost kao modulatora receptora ep4 | |
| IL240417A0 (en) | Converted benzamides with activity towards ep4 receptors | |
| HRP20181596T1 (hr) | Tiazolopirimidinoni kao modulatori aktivnosti nmda receptora | |
| HK1202540A1 (en) | Heteroaromatic methyl cyclic amine derivative | |
| HK1204609A1 (en) | Carbamate urea derivatives | |
| EP2909181A4 (en) | PKM2 MODULATORS AND METHODS OF USING SAME | |
| HUE049728T2 (hu) | Benzofurán-2-szulfonamid származékok, mint kemokin receptor modulátorok | |
| HK1208028A1 (en) | Novel acetamide derivatives as trp channel antagonists trp |